Fennec Pharmaceuticals Inc. - Common Stock (NQ:FENC)

10.41 +0.06 (+0.58%)

Delayed Quote Updated: 10:44 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fennec Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 Next >

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Highlighted for Surprising Price Action

March 18, 2024

Via Investor Brand Network

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Making Surprising Moves in Monday Session

November 06, 2023

Via Investor Brand Network

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Preview: Fennec Pharmaceuticals's Earnings ↗

November 03, 2023

Via Benzinga

Analyst Ratings for Fennec Pharmaceuticals ↗

June 21, 2023

Via Benzinga

Recap: Fennec Pharmaceuticals Q1 Earnings ↗

May 11, 2023

Via Benzinga

Earnings Outlook For Fennec Pharmaceuticals ↗

May 10, 2023

Via Benzinga

Analyst Ratings for Fennec Pharmaceuticals ↗

April 06, 2023

Via Benzinga

7 Biotech Stocks Sitting in the Sweet Spot ↗

March 24, 2023

Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable.

Via InvestorPlace

Expert Ratings for Fennec Pharmaceuticals ↗

November 22, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals ↗

November 22, 2022

Via Benzinga

4 Analysts Have This to Say About Fennec Pharmaceuticals ↗

November 22, 2022

Via Benzinga

US Stocks Open Lower; Dow Dips 250 Points ↗

January 25, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.74% to 33,484.47 while the NASDAQ fell...

Via Benzinga

Where Fennec Pharmaceuticals Stands With Analysts ↗

November 22, 2022

Via Benzinga

Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday ↗

September 22, 2022

Gainers

Via Benzinga

After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss ↗

September 21, 2022

Via Benzinga

Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session ↗

September 21, 2022

Gainers

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022 ↗

September 07, 2022

Upgrades

Via Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

NASDAQ:FENC Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Fennec Pharmaceuticals Inc. ↗

June 01, 2022

San Diego, CA -- (SBWIRE) -- 06/01/2022 -- Certain directors of Fennec Pharmaceuticals Inc. are under investigation over potential breaches of fiduciary duties.

Via SBWire

U.S. FDA accepts Fennec Pharma's New Drug Application (NDA) Resubmission for PEDMARK ↗

April 27, 2022

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) announced that the U.S.

Via Benzinga

NASDAQ:FENC Shareholder Notice: Deadline on April 11, 2022 in Lawsuit Against Fennec Pharmaceuticals Inc. ↗

April 11, 2022

San Diego, CA -- (SBWIRE) -- 04/11/2022 -- A deadline is coming up on April 11, 2022 in the lawsuit filed for certain investors of Fennec Pharmaceuticals Inc. (NASDAQ:FENC).

Via SBWire

FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm

April 11, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

FENC FINAL DEADLINE APRIL 11: NATIONALLY RANKED ROSEN LAW FIRM Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - FENC

April 09, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)

April 08, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FENC

April 04, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗

March 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FENC

March 11, 2022

WHY: NEW YORK, NY - (NewMediaWire) - March 11, 2022 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...

Via NewMediaWire

Topics Lawsuit

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fennec Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - FENC

March 04, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Investor Notice: Lawsuit Alleges Violations of Securities Laws ↗

February 24, 2022

San Diego, CA -- (SBWIRE) -- 02/24/2022 -- An investor, who purchased NASDAQ:FENC shares, filed a lawsuit against Fennec Pharmaceuticals Inc. over alleged violations of Federal Securities Laws.

Via SBWire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.